A Phase 1b/2 Study of GS-5829 in Combination With Fulvestrant or Exemestane in Subjects With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Trial Profile

A Phase 1b/2 Study of GS-5829 in Combination With Fulvestrant or Exemestane in Subjects With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs GS 5829 (Primary) ; Exemestane; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 22 May 2017 Treatment arms has been decreases from 6 to 4. Patients number also decreases.
    • 22 May 2017 Planned number of patients changed from 180 to 150.
    • 22 May 2017 Planned End Date changed from 1 Oct 2020 to 1 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top